Anixa Biosciences, Inc. — Q2 FY2023 10-Q Summary
Reporting period: Quarter and six months ended April 30, 2023. Unless otherwise noted, financial amounts below are in U.S. dollars; statement amounts are in thousands. Anixa is a clinical-stage biotechnology company developing cancer vaccines and CAR-T therapies, with limited legacy patent-licensing activity.
Financial performance and liquidity
| Metric | Three months ended Apr. 30, 2023 | Six months ended Apr. 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $210,000 | $210,000 | $0 |
| Operating costs and expenses | $2.770 million | $5.326 million | $3.589 million / $7.469 million |
| Operating loss | $2.560 million | $5.116 million | $3.589 million / $7.469 million |
| Net loss attributable to common shareholders | $2.288 million | $4.610 million | $3.544 million / $7.373 million |
| Basic and diluted loss per share | $0.07 | $0.15 | $0.12 / $0.24 |
The $210,000 revenue came from a one-time legacy technology license agreement; the company reported no revenue from its vaccine or therapeutic programs. Gross margin is not separately presented, and the filing does not provide a meaningful recurring-product margin.
- Research and development expense was $998,000 for the quarter and $2.066 million for six months, down from $1.735 million and $3.573 million, respectively, in 2022. General and administrative expense was $1.611 million and $3.099 million, versus $1.854 million and $3.896 million.
- Interest income was $253,000 for the quarter and $455,000 for six months, compared with $1,000 and $2,000 in 2022, primarily reflecting higher interest rates. Stock-based compensation remained a material non-cash expense: $1.227 million for the quarter and $2.290 million for six months.
- At April 30, cash and cash equivalents were $5.620 million and short-term investments were $21.356 million, totaling $26.976 million. Total current assets were $27.410 million; current liabilities were $1.537 million. Total liabilities were $1.686 million, including operating lease liabilities; the filing reports no conventional debt balance.
- Six-month operating cash use was $2.795 million. Investing activities used $4.029 million net, mainly reflecting purchases of short-term investments in excess of maturities; financing provided $84,000. Cash and cash equivalents declined $6.740 million, while cash plus short-term investments declined approximately $2.711 million from fiscal year-end.
Material changes and business developments
- Compared with the prior-year periods, quarterly and six-month net losses narrowed. Lower R&D and G&A expenses were partly offset by the modest, nonrecurring license revenue and higher interest income; reductions in stock-based compensation contributed to lower expenses.
- The company paused further development of its COVID-19 antiviral program on March 9, 2023. Management cited inadequate oral bioavailability in animal studies, uncertainty about developing an oral treatment, limited commercial prospects for an injectable alternative, and the need to prioritize resources. Patent applications continue, and development could resume.
- The breast-cancer vaccine Phase 1 study reached its maximum tolerated dose in December 2022. In April 2023, the company reported antigen-specific T-cell responses at all dose levels among participants tested to date; it expanded dose cohorts and began recruiting for a second stage involving people without prior cancer but with certain high-risk genetic mutations.
- The ovarian-cancer CAR-T Phase 1 trial treated its second patient in May 2023 at the initial dose level; treatment appeared well-tolerated in both patients treated to date. Recruitment is ongoing. The study is planned for 24–48 patients, with completion estimated at two to four years depending on recruitment, dose escalation and other factors.
- The ovarian-cancer vaccine’s preclinical work is being supported by the National Cancer Institute’s PREVENT program; the company says this work is expected to require no material company expenditure.
Outlook, risks and contingencies
- Management stated, based on information available as of June 14, 2023, that existing cash, cash equivalents, short-term investments and expected cash flows should fund activities for at least the next 12 months. This is an estimate, not a guarantee; the company cautions that actual cash needs and flows may differ.
- Anixa does not expect near-term revenue from its current vaccine or therapy programs. Potential future commercialization depends on development progress, positive clinical results and possible licensing, which may take years or may not occur.
- The company may seek additional capital through equity or debt. Its at-the-market program authorized sales of up to $100 million of common stock; no shares were sold under it during the reported quarter or six-month period. Future equity or convertible-debt financing could dilute shareholders, and funding may not be available on acceptable terms.
- Patent-enforcement lawsuits are part of its activities. Apart from those matters, Anixa reported no material pending legal proceedings expected to materially adversely affect its financial condition or results. It reported no material changes to previously disclosed risk factors.
- Management reported effective disclosure controls as of period-end and no material change in internal control over financial reporting during the quarter. The filing notes that federal and California tax-loss carryforwards may be subject to limits under Internal Revenue Code Section 382; the effects have not been determined.
Important facts for investors to verify
- Whether the stated minimum 12-month funding runway remains supportable as clinical-trial spending and cash balances change.
- Clinical-trial enrollment, safety, immune-response data and milestones for the breast-cancer vaccine and ovarian-cancer CAR-T programs.
- Whether any new recurring licensing revenue or partner funding emerges, given the one-time nature of the period’s $210,000 revenue and the lack of program revenue to date.
- Potential dilution from the at-the-market program or other financing, as well as the number of outstanding options and future equity awards.
- How the antiviral-program pause and any patent-enforcement activity affect future spending, licensing opportunities and contingencies.